Repligen (NASDAQ:RGEN) Updates FY 2026 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.970-2.050 for the period, compared to the consensus estimate of 1.970. The company issued revenue guidance of $803.0 million-$833.0 million, compared to the consensus revenue estimate of $827.9 million.

Repligen Trading Up 0.9%

NASDAQ:RGEN opened at $118.21 on Tuesday. Repligen has a 12-month low of $109.50 and a 12-month high of $175.77. The firm has a market capitalization of $6.67 billion, a P/E ratio of 139.07, a P/E/G ratio of 2.28 and a beta of 1.09. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. The business has a 50 day simple moving average of $121.56 and a 200 day simple moving average of $144.68.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The business had revenue of $194.26 million during the quarter, compared to analyst estimates of $192.05 million. During the same quarter in the previous year, the firm posted $0.39 EPS. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities research analysts predict that Repligen will post 1.97 EPS for the current year.

Analysts Set New Price Targets

RGEN has been the subject of a number of analyst reports. HC Wainwright boosted their price target on Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. Wells Fargo & Company reduced their price target on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Barclays reduced their price target on Repligen from $175.00 to $145.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Finally, Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average target price of $170.25.

Institutional Investors Weigh In On Repligen

Institutional investors and hedge funds have recently modified their holdings of the stock. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen during the third quarter worth $29,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the fourth quarter worth $36,000. Itau Unibanco Holding S.A. raised its position in shares of Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 104 shares during the period. Johnson Financial Group Inc. acquired a new position in Repligen during the third quarter valued at $65,000. Finally, Wilmington Savings Fund Society FSB raised its position in Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 495 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.